First prescriber data since FDA hearings shows that while cost and injection method concerns exist, 76% of cardiologists are very excited, 52% consider it a “triumph of modern genetic revolution” […]
A tepid recommendation from an expert advisory panel could limit the sales of new cholesterol drugs, but they could still become $1 billion products in the near term, and generate […]
